Objective. The aim of this study was to assess whether baseline characteristics in patients with undifferentiated arthritis or early RA affect the possibility of achieving drug-free remission after 1 year (DFR 1 year ) of early remission induction therapy. Methods. We included 375 patients participating in the IMPROVED study who achieved remission (DAS < 1.6) after 4 months (early remission) and were by protocol able to achieve DFR 1 year . Having started with MTX plus prednisone, patients tapered prednisone to zero; after 8 months, those still in remission tapered MTX to zero, while those not in remission restarted prednisone. Characteristics of patients achieving and not achieving DFR 1 year were compared. Logistic regression was performed to identify predictors of DFR 1 year .
Introduction
With current treatment strategies, remission has become a realistic goal in patients with RA [13] . It remains to be seen whether achieving drug-free remission (DFR) after tapering medication is also a realistic goal. In recent cohort studies and clinical trials in patients with RA, DFR rates vary between 17% and 29% [46] and DFR was sustained for 14 years in 916% of patients [4, 7] . Previously reported independent predictors for sustained DFR are: absence of ACPAs, RF and shared epitope; short symptom duration; and low disease activity until remission [6, 7] .
In the IMPROVED study, patients with recent-onset RA or undifferentiated arthritis (UA) clinically suspected for RA received initial treatment with a combination of MTX and a tapered high dose of prednisone. If remission (DAS < 1.6) was achieved after 4 months, medication was stepwise tapered until DFR could be achieved after 1 year (DFR 1 year ).
We previously reported that 61% of the patients achieved early remission after 4 months. Surprisingly, these patients were more often ACPA-positive than the patients who did not achieve early remission [8] . Here, we aimed to assess whether ACPA status also influenced the likelihood of achieving DFR 1 year and of identifying other possible determinants of achieving DFR 1 year .
Methods
Patients, study design and outcomes IMPROVED is a multi-centre clinical trial in 122 patients with UA and 479 patients with recent-onset RA (2010 criteria), treated according to a tightly controlled, remissionsteered (DAS < 1.6 [9] ) protocol. Details on in-and exclusion criteria have been previously published [10] . Initially, all patients were treated with MTX 25 mg/week plus prednisone 60 mg/day tapered in 7 weeks to 7.5 mg/day, continued up to 4 months. Patients not in remission after 4 months by protocol could not achieve DFR 1 year because they had to take additional treatment steps before tapering was possible, and thus were left out of the current analysis. Patients who achieved remission after 4 months (early remission) first tapered prednisone to zero in 4 weeks; if still in remission after 8 months, they also tapered MTX to zero in 2 months . Patients who lost remission while still on MTX restarted prednisone, and patients who had already discontinued MTX restarted MTX. DFR 1 year was defined as having a DAS < 1.6 from 4 months to 1 year while both prednisone and MTX were subsequently tapered and stopped. Because DFR 1 year was only achieved about 2 months before the end of year 1, we included 16 months follow-up data to see if DFR could be sustained. Details on the study protocol and scoring methods have been previously published [11] . The medical ethics committees of each participating centre approved the study, and all patients gave written informed consent.
Statistical analysis
Clinical, radiological and laboratory variables during the first year were compared between patients achieving and not achieving DFR 1 year using Student's t-test, the MannWhitney U-test and chi-square test. All available baseline clinical, demographic and laboratory characteristics were entered as covariates in univariate logistic regression analyses, with DFR 1 year as binomial dependent variable. Using a significance level of 0.10, univariate significant variables were entered in a multivariable model to identify independent predictors.
Results
After 4 months, 375 patients (61%) achieved early remission, of which 291 (78%) fulfilled the 2010 classification criteria for RA. Compared with patients not in early remission, patients in early remission had lower mean baseline DAS and HAQ levels, more were ACPA-positive and fewer were female [8] . After 1 year, 119/375 patients (32%) were in DFR, and 245 (65%) were not, although 138 (56%) of those were in remission but on medication. There were insufficient data for 11 of the patients. (Table 1) .
Results of the univariate regression analysis are shown in Table 2 . Baseline DAS and HAQ values, ACPA status, age, male sex, and symptom duration were not associated with achieving DFR 1 year . RF positivity, high baseline tender joint count (TJC), and fulfilling the 2010 criteria for RA were univariate predictive for less often achieving DFR 1 year . In a multivariate regression model, none of these variables was independently predictive of less often achieving DFR 1 year [adjusted odds ratio (OR) (95% CI) RF positivity 0.6 (0.41.1), baseline TJC 0.9 (0.91.0), fulfilling the 2010 criteria for RA 0.9 (0.51.8)]. After leaving out the least significant variable, fulfilling the 2010 criteria for RA (P = 0.8), RF positivity was predictive of less often achieving DFR 1 year , independently of TJC.
A total of 77 patients (65%) in DFR 1 year were still in DFR after 16 months (DFR 16 mo ), 36 (30%) were not, and 6 patients had missing data. Those who lost remission were more often ACPA-positive than those who sustained DFR [26 (72%) vs 36 (47%), P = 0.01], and ACPA-positive patients less often sustained remission than ACPAnegative patients [36 (58%) vs 40 (80%), P = 0 
Discussion
In the IMPROVED study, 32% of the early arthritis patients who had achieved remission after 4 months were able to maintain remission and taper all medication to DFR 1 year , regardless of fulfilling the 1987 and/or 2010 classification criteria for RA. Baseline characteristics in the past associated with chronic and/or progressive disease (such as being RF positive and fulfilling criteria for RA) were associated with less often achieving DFR 1 year , although not independently of each other. Also, a high TJC at baseline was non-independently associated with less often achieving DFR 1 year . ACPA status and symptom duration were not associated with DFR 1 year . In 65% of patients in DFR 1 year , DFR was sustained for 4 more months. Although DFR was achieved in ACPA-positive patients as often as in ACPA-negative patients, ACPA-positive patients less often remained in DFR than ACPA-negative patients.
To our knowledge, IMPROVED is the first study in which DFR was a treatment goal. A DFR rate of 32% after 1 year is probably high, although 29% of the total IMPROVED population did not achieve early remission after 4 months and by protocol were not able to achieve DFR even after 1 year.
Given the fact that we included both RA and UA patients clinically suspected for RA but not fulfilling the criteria, we may have included and treated patients who might have remitted spontaneously. This was a reason why we introduced a rapid drug tapering scheme in our protocol. However, if the 32% mainly represented nonchronic types of arthritis, one would expect that these patients were more often autoantibody negative, possibly had shorter disease duration, or less often fulfilled the criteria sets for RA than patients not achieving DFR, which was not the case.
Interestingly, the presence of ACPA was not associated with less DFR 1 year . Previously we reported that the presence of ACPA was associated with achieving more remission after 4 months in the IMPROVED study [8] , which was in contrast with previous data indicating that the presence of ACPA was associated with a less favourable disease course [13, 14] . In a study comparing DFR in the Leiden Early Arthritis Clinic and the BeSt study, absence rather than presence of ACPA was an independent predictor of (830) 17 (932) sustained DFR [7] . That ACPA-positive patients achieved DFR 1 year at a similar rate to that of ACPA-negative patients may be explained by both the initial combination of MTX and prednisone and the early remission-steered treatment in the IMPROVED study. However, after treatment was stopped, 30% of patients lost remission and had to restart medication within 4 months after achieving DFR, and ACPA-positive patients more often lost DFR than ACPA-negative patients. This suggests that compared with ACPA-negative patients, ACPA-positive patients have a similar likelihood of achieving and maintaining remission, even while medication is tapered. But after having successfully tapered and discontinued medication, ACPA-positive patients show more relapses in disease activity in the next 4 months, and this may even increase with follow-up. Reasons why sustained DFR was achieved less often in ACPA-positive patients may be that we have tapered medication too soon or too quickly or have not used the optimal initial treatment within the optimal time frame. In the future, when follow-up data up to 5 years will become available, we will be able to see which of the patients who did not achieve early remission by 4 months, have achieved late DFR in the randomization arms and whether this is sustained over time.
In conclusion, 32% of patients with early arthritis who achieved remission after 4 months of initial combination therapy can taper medication until DFR is achieved after 1 year. Achieving DFR is possible regardless of ACPA status or other baseline disease characteristics, but DFR is sustained less often in ACPA-positive than in ACPA-negative patients. Three-month isolated digital gangrene as an initial manifestation of classic polyarteritis nodosa A 71-year-old man presented with digital gangrene worsening over 2 months (Fig. 1A and B) . The bilateral radial arteries were palpable, but the left posterior tibial artery and bilateral dorsalis pedis arteries were not convincingly palpable. Neurological examination was normal and there were no skin lesions. Serum creatinine, serological evaluation of autoimmune and haematological diseases causing digital gangrene and urine test were normal. Contrastenhanced thoraco-abdominal CT revealed nothing significant. Angiography showed stenosis or obstruction of the palmar arch, plantar arch and arcuate artery without the corkscrew collaterals ( Fig. 1C and D) . Three months after the onset, right peroneal nerve paralysis occurred. Nerve conduction studies suggested mononeuritis multiplex. Biopsy of right peroneus brevis muscle and right peroneal nerve revealed vasculitic neuropathy consistent with PAN. Four months after the onset he had macroscopic haematuria, proteinuria and elevation of serum creatinine. A diagnosis of classic PAN was made. Inflammation subsided and renal function improved after treatment with oral prednisolone and i.v. CYC. His necrotic fingers were amputated, but the toes recovered completely. Although digital gangrene is a very rare manifestation of classic PAN [1] , it could be the only symptom of this disease at the early stage.
